Sware, a Boston, MA-based provider of a software validation solution for innovative life sciences companies, raised $6M in Series B funding.
The round was led by First Analysis, with participation from existing investors including LRVHealth, New Stack Ventures and Insight Partners. As a result of the funding, Matt Nicklin, managing director at First Analysis, will join the company’s board of directors.
The company intends to use the funds to bolster research and development of its computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand its sales team.
Led by CEO Ellen Reilly, Sware provides Res_Q™, a software platform that offers complete validation solution eliminating validation debt. With it, the company enables pharmaceutical, medical device and biotechnology companies to automate, integrate and scale their validation processes. It is a cloud-based platform built with an open API architecture that allows organizations to control all validation processes – for IT, manufacturing, lab systems, and more – in a single system.
FinSMEs
07/06/2024